AbstractHurler syndrome (HS) is a severe inborn error of metabolism causing progressive multi-system morbidity and death in early childhood. At present, stem cell transplantation (SCT) is the only available treatment that can prevent central nervous system disease progression in HS patients. Although SCT has been shown to be effective for several important clinical outcome parameters, the reported clinical outcome after successful SCT is variable among HS patients and there are still some major limitations.This review will focus on the clinical outcome of HS patients after successful SCT, with particular emphasis on the long-term outcome and complications. In addition, factors that are suggested to contribute to the variable outcome are out...
The most severe form of Mucopolysaccharosidosis type I (MPS-I), Hurler syndrome, presents with progr...
We report a retrospective analysis of 53 haematopoietic stem cell transplants for inherited metaboli...
Purpose: Early treatment is critical for mucopolysaccharidosis type I (MPS I), justifying its incorp...
AbstractHurler syndrome (HS) is a severe inborn error of metabolism causing progressive multi-system...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Hurler syndrome is a severe inherited metabolic disorder caused by a deficiency of the lysosomal enz...
AbstractAllogeneic stem cell transplantation (SCT) is considered effective in preventing disease pro...
ABSTRACT Hematopoietic stem cell transplantation (HSCT) is the only available treatment for the neur...
Hurler syndrome (HS) is a lysosomal storage disease characterized by multisystem morbidity and death...
Mucopolysaccharidosis type I (MPS I; Hurler syndrome) is a lysosomal storage disease caused by a def...
The article describes the transplantation of hematopoietic stem cells (HSC) in children with severe ...
ence progressive neurologic deterioration and early death. Allogeneic bone marrow transplantation (B...
AbstractAllogeneic stem cell transplantation (SCT) is considered effective in preventing disease pro...
The most severe form of Mucopolysaccharosidosis type I (MPS-I), Hurler syndrome, presents with progr...
We report a retrospective analysis of 53 haematopoietic stem cell transplants for inherited metaboli...
Purpose: Early treatment is critical for mucopolysaccharidosis type I (MPS I), justifying its incorp...
AbstractHurler syndrome (HS) is a severe inborn error of metabolism causing progressive multi-system...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized b...
Hurler syndrome is a severe inherited metabolic disorder caused by a deficiency of the lysosomal enz...
AbstractAllogeneic stem cell transplantation (SCT) is considered effective in preventing disease pro...
ABSTRACT Hematopoietic stem cell transplantation (HSCT) is the only available treatment for the neur...
Hurler syndrome (HS) is a lysosomal storage disease characterized by multisystem morbidity and death...
Mucopolysaccharidosis type I (MPS I; Hurler syndrome) is a lysosomal storage disease caused by a def...
The article describes the transplantation of hematopoietic stem cells (HSC) in children with severe ...
ence progressive neurologic deterioration and early death. Allogeneic bone marrow transplantation (B...
AbstractAllogeneic stem cell transplantation (SCT) is considered effective in preventing disease pro...
The most severe form of Mucopolysaccharosidosis type I (MPS-I), Hurler syndrome, presents with progr...
We report a retrospective analysis of 53 haematopoietic stem cell transplants for inherited metaboli...
Purpose: Early treatment is critical for mucopolysaccharidosis type I (MPS I), justifying its incorp...